Adjuvant Radiotherapy After Mastectomy With a Positive Sentinel Node and No Axillary Dissection
A 48-year-old premenopausal woman underwent mastectomy for a 2.5 cm, grade 3, ER-positive, HER2-negative invasive ductal carcinoma. Sentinel lymph node biopsy showed one of three nodes with a 4 mm macrometastasis; no axillary dissection was performed. Margins are negative (closest 4 mm). She is scheduled for adjuvant radiotherapy to the chest wall. The question is whether to include the regional nodes (supraclavicular, infraclavicular, and internal mammary) and whether to add a boost. She has a strong family history but no genetic testing yet. The radiation oncologist must decide the target volumes before simulation.
1. Should regional nodal irradiation be included in this patient, and what evidence and patient factors drive the decision?
Read the worked answer
This patient has one macrometastatic sentinel node without axillary dissection, which places her at meaningful risk of additional nodal disease and regional recurrence. The decision to include regional nodes should be individualized using the results of the EORTC 22922/10925 and MA.20 trials, which showed that regional nodal irradiation reduces regional and distant recurrence at the cost of increased lymphedema and pneumonitis, with a modest overall survival benefit in some subgroups.
Favorable features for RNI here: grade 3 histology, macrometastasis (4 mm), premenopausal status, and no axillary dissection (so the axilla has not been surgically cleared). Unfavorable features: only one positive node and ER-positive disease (systemic therapy will contribute).
A reasonable approach is to include the supraclavicular and infraclavicular nodes and give strong consideration to the internal mammary chain, because the internal mammary nodes are a common site of occult involvement in medially located or node-positive tumors and were included in the MA.20/EORTC volumes. The final decision should weigh her cardiac and pulmonary risk (left-sided vs right-sided, internal mammary dose to the heart) and be discussed in a multidisciplinary setting. Document the rationale in the chart.
2. How would you decide on a tumor bed boost after mastectomy, and what does the family history change, if anything?
Read the worked answer
After mastectomy, a tumor bed boost is not routine. The indications for a chest wall boost are high-risk features: close or positive margins, large tumor size, high grade, lymphovascular invasion, and young age. This patient has a 4 mm closest margin (negative but close), grade 3 histology, and is premenopausal, so a boost to the mastectomy scar/tumor bed is reasonable and often recommended in this setting, particularly if the chest wall dose is standard (50 Gy in 25 fractions) and the boost can be delivered with electrons or photons to a limited volume.
The family history does not by itself change the radiation target volumes, but it raises the possibility of a hereditary breast cancer syndrome (BRCA1/2, PALB2, TP53, PTEN). Genetic testing should be pursued because it affects systemic therapy, contralateral risk, and possibly the choice of local therapy. If a TP53 mutation is found, the risk of radiation-induced second malignancy is a consideration, though not an absolute contraindication to adjuvant RT. The boost decision should be made on pathologic risk, not on family history alone.